Insomnia medication to reduce brain damage markers in adults
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial tests whether a medication that blocks brain chemicals involved in wakefulness can help reduce markers of nerve damage in people with insomnia. It is for adults aged 40–65 with chronic insomnia, and it aims to see if improving sleep may protect brain health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with insomnia (trouble sleeping at least 3 nights a week for 3 months or more) and scored 15 or higher on a sleep questionnaire.
- You are between the ages of 40 and 65.
- You are not having untreated moderate-severe sleep apnea, or if you have sleep apnea it is being treated effectively.
- You are not currently taking certain medications (like specific sleep aids, antidepressants, stimulants, or opioids) and can stop them for at least 2 weeks before the trial.
- You have no history of suicide attempts or current suicidal thoughts, and no untreated serious mental health conditions or other sleep disorders like narcolepsy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a part of the brain called the locus coeruleus is involved in insomnia. It involves sleep questionnaires and possibly brain imaging to understand your sleep problems better.
This trial tests a new inhaled form of melatonin to help adults aged 55 and older with insomnia fall asleep faster. It compares the inhaled melatonin to a placebo to see if it improves sleep and is safe.
This study tests if lemborexant, a sleep medication, can help people with both a mental health condition and insomnia. You would take the medicine as prescribed and complete questionnaires over 2 months.
This trial tests whether a medication called Lemborexant can improve sleep problems and movement symptoms in people with Parkinson's disease. If you have trouble sleeping due to insomnia and have had Parkinson's for at least 2 years, this study may help.
This trial tests if the sleep medication lemborexant can help people with early-stage dementia who also have insomnia. It uses an N-of-1 design, meaning it will look at how you personally respond to the drug compared to a placebo.
This study tests if the sleep medication lemborexant can help people with opioid use disorder who also have chronic insomnia. Participants must already be taking buprenorphine (Suboxone) for at least 4 weeks. The goal is to see if better sleep improves mood and reduces opioid use.
Hear when a new Insomnia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.